XCancer

177-Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (Lunar)

Description:

This phase II trial tests whether 177-Lutetium-PSMA given before stereotactic body radiotherapy (SBRT) works to improve cancer control rate in patients with 1-5 prostate cancer tumors that have come back after prior treatment (oligorecurrent). Radioactive drugs, such as 177-Lutetium-PSMA, may carry radiation directly to tumor cells and not harm normal cells. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving 177-Lutetium-PSMA before SBRT may make the SBRT more effective.

Sponsor:

Jonsson Comprehensive Cancer Center (UCLA)

Phase:

Phase 2

Contacts:

Rejah Marie Nabong (Clinical Research Manager)

rmalano@mednet.ucla.edu

3102067372

Kiara Booker (Clinical Research Coordinator)

kmbooker@mednet.ucla.edu

Government Study Link:

NCT05496959 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • Oligorecurrent prostate cancer as determined by the presence of 1-5 asymptomatic lesions outside the prostate or bed
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Histologic confirmation of prostate adenocarcinoma (histology from original treatment acceptable)
  • No indication for urgent or emergent radiation
Exclusion
  • Patients who received androgen deprivation therapy within 6 months of trial enrollment
  • Patients with castrate-resistant disease (i.e., PSA > 0.5 ng/mL with serum testosterone < 150 ng/dL)
  • Concurrent systemic therapy for a solid organ malignancy
  • Known hypersensitivity to components of 177Lu-PNT2002
  • Patients with neuroendocrine or small cell carcinoma of the prostate

Patient Education

Patient Education Not Yet Provided

Publications

Publication 1

Locations

Loading...